Quest Diagnostics Data Highlights Growing Role of ctDNA MRD in Colorectal Cancer Management
Event summary
- Quest Diagnostics will present data on circulating tumor DNA (ctDNA) minimal residual disease (MRD) testing at the 2026 ASCO Gastrointestinal Cancers Symposium, January 8-10.
- Two poster presentations will focus on the Haystack MRD® test's performance in colorectal cancer patients, one evaluating reproducibility and the other monitoring patients undergoing total neoadjuvant treatment (TNT).
- The Haystack MRD test, developed by Haystack Oncology (a Quest Diagnostics subsidiary), detects ultralow levels of ctDNA.
- A recent survey indicated 96% of oncologists believe MRD testing has the potential to identify cancer recurrence earlier than current methods.
The big picture
The increasing use of ctDNA MRD testing represents a significant shift towards more personalized and proactive cancer management. Quest Diagnostics' acquisition of Haystack Oncology positions them to capitalize on this trend, but the market is becoming increasingly competitive. The ability to demonstrate clinical utility and secure favorable reimbursement will be key to long-term success.
What we're watching
- Clinical Adoption
- The data presented at ASCO will be crucial in driving broader clinical adoption of ctDNA MRD testing, particularly as reimbursement models evolve for lab-developed tests (LDTs).
- Competitive Landscape
- The success of Haystack MRD will depend on its ability to maintain a competitive edge against other emerging liquid biopsy platforms and established diagnostic players.
- Regulatory Scrutiny
- Increased regulatory scrutiny of LDTs could impact the commercial availability and reimbursement of Haystack MRD, requiring Quest Diagnostics to navigate evolving guidelines.
